Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) announced that it has completed patient enrollment in the second cohort of an ongoing phase II study on PSMA ADC for the treatment of prostate cancer. The company enrolled 36 chemotherapy naive patients suffering from prostate cancer, whose disease had progressed after hormonal therapies. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) weekly performance is -2.22%. On last trading day company shares ended up $3.52. Analysts mean target price for the company is $ 9.50. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) distance from 50-day simple moving average (SMA50) is -13.04%.
Baxano Surgical, Inc. (NASDAQ:BAXS) a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region, today announced its financial results for the first quarter ended March 31, 2014. On May 31, 2013, we consummated our acquisition of Baxano, Inc. Our consolidated statements of operations reflect the Baxano, Inc. results, including the iO-Flex(R) and iO-Tome(R) products, from May 31, 2013. Baxano Surgical Inc (NASDAQ:BAXS) shares fell -14.13% in last trading session and ended the day on $0.687. BAXS Gross Margin is 69.90% and its return on assets is -69.20%. Baxano Surgical Inc (NASDAQ:BAXS) quarterly performance is -47.56%.
Intuitive Surgical, Inc. (NASDAQ:ISRG) reported that equity awards approved by the Compensation Committee of the Board of Directors, which consists entirely of Independent Directors, were made to 63 new employees. Pursuant to NASDAQ Marketplace Rule 5635(c)(4), the equity awards were granted under the Intuitive Surgical, Inc. 2009 Commencement Incentive Plan, which the Board of Directors of Intuitive Surgical, Inc. adopted for the granting of equity awards to new employees. Intuitive Surgical, Inc. (NASDAQ:ISRG) shares moved up 0.20% in last trading session and was closed at $353.06, while trading in range of $346.46 – $353.30 -. Intuitive Surgical, Inc. (NASDAQ:ISRG) year to date (YTD) performance is -8.08%.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported business and financial highlights for the first quarter ended March 31, 2014. Celldex Therapeutics, Inc. (NASDAQ:CLDX) ended the last trading day at $12.79. Company weekly volatility is calculated as 11.49% and price to cash ratio as 3.77. Celldex Therapeutics, Inc. (NASDAQ:CLDX) showed a negative weekly performance of -11.85%.
Leave a Reply